AI prepares to change CV risk prevention

Artificial intelligence (AI) is usually applied to analyze a complex set of variables to make correlations that are not easily made by unsupported observation. But the branch of artificial intelligence, sometimes referred to as causal AI, includes not only causation, and appears to have the potential to change the cardiovascular (CV) event prevention paradigm. Ference, … Read more

Automated pathology device moving forward in approval

A pathologist may welcome a new robotic co-worker soon. Clarapath Corporationa New York-based biotechnology company, has created a tool called Section To automate the pathology process. The device has not yet entered the market and is currently under review by the US Food and Drug Administration (FDA). Clarabeth Inc Star Division. Eric Feinstein, CEO of … Read more